Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director

Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director

Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director 1668 2500 Eyevensys

Paris (France), 13th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, announces today the appointment of Thierry Bordet, Ph.D. as Pre-Clinical Director.

Thierry will be directing Eyevensys’ pre-clinical development efforts, including the generation of potential clinical candidates for the range of eye diseases that the Company is targeting such as retinal vein occlusion and retinitis pigmentosa. He will also oversee Eyevensys’ relationships with potential academic and industrial partners.

Thierry brings more than 15 years’ experience in the biotechnological sector having managed drug development programs for small molecules, gene therapies, cell-based therapies and tissue engineered products. He was most recently Pre-Clinical Development Director at the Biotherapies Institute for Rare Diseases, in Evry, France where he designed development strategies for advanced therapy medicinal products for various indications, including inherited retinitis pigmentosa. Prior to that he spent 12 years at Trophos managing the company’s drug screening and early development programs for neurodegenerative indications. Thierry has a Ph.D. in microbiology and virology from Pierre & Marie Curie University PARIS VI.

Raffy Kazandjian, CEO of Eyevensys, said, “I am pleased to welcome Thierry to the team. Eyevensys has a unique approach to treating ophthalmic diseases based around our proprietary EyeCET platform. Our objective is to leverage our unique technology to rapidly build a comprehensive portfolio of products that will target a range of major eye diseases; and Thierry’s extensive pre-clinical research experience, as well as years of direct involvement in the development of gene therapies will be a great asset to move several of our products forward.”